Interstitial Lung Disease in Anti-Synthetase Syndrome

Evangelia Kourkouni; Georgios Mitsogiannis; Theodora Simopoulou; Christos Liaskos; Christina G Katsiari; Zoi Daniil; Konstantinos Gourgoulianis; Dimitrios P Bogdanos; Lazaros I Sakkas

doi:10.31138/mjr.30.3.186

Interstitial Lung Disease in Anti-Synthetase Syndrome

Mediterr J Rheumatol. 2019 Sep 30;30(3):186-189. doi: 10.31138/mjr.30.3.186. eCollection 2019 Sep.

Authors

Evangelia Kourkouni¹, Georgios Mitsogiannis¹, Theodora Simopoulou¹, Christos Liaskos¹, Christina G Katsiari¹, Zoi Daniil², Konstantinos Gourgoulianis², Dimitrios P Bogdanos¹, Lazaros I Sakkas¹

Affiliations

¹ Department of Rheumatology and Clinical Immunology.
² Department of Respiratory Medicine, University General Hospital of Larissa, Faculty of Medicine, University of Thessaly, Larissa, Greece.

Abstract

Anti-synthetase syndrome is an autoimmune disorder characterized by the presence of autoantibodies against aminoacyl transfer RNA (tRNA) synthetases, and myositis, interstitial lung disease (ILD), arthritis, fever and Raynaud's phenomenon (RP). We present a 54-year-old woman, who complained of fatigue, low-grade fever, myalgias, arthralgias, RP and dyspnoea on exertion. Chest CT scan revealed features of interstitial lung disease. Due to rapid deterioration of her lung function, she required oxygen support. The patient did not respond to empiric treatment with antibiotics. Autoantibody testing was remarkable for ANA positivity (1/160) and high-titre anti-Jo1 positivity. A diagnosis of anti-synthetase syndrome was made and the patient was placed on high-dose corticosteroids and rituximab with significant improvement. At 1-year follow up, she remains in good condition, without the need for oxygen supplementation.

Keywords: Raynaud’s phenomenon; anti-Jo1; anti-synthetase syndrome; interstitial lung disease.

Publication types

Case Reports